TPST
Companies
NASDAQ
Tempest Therapeutics Inc.
Health Care
$6.90
-$3.96 (-36.43%)
Price Chart
Overview
About TPST
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
Market Cap
$69.1M
Volume
332.1K
Avg. Volume
429.7K
P/E Ratio
-4.8550725
Dividend Yield
0.00%
Employees
18.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.64
High Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, TPST shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$69.1M
Volume332.1K
P/E Ratio-4.86
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 14, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025